the First Affiliated Hospital of Nanjing Medical University
近年来原发性肺癌的靶向药物研究飞速发展,其中针对表皮生长因子受体(Epidermal Growth Factor Receptor,EGFR)基因靶点的药物EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors,EGFR-TKI)对绝大多数EGFR突变型患者有很好的疗效。但EGFR-TKI对于野生型患者或者耐药性突变患者疗效甚微。因此行靶向治疗之前必须对EGFR突变状态进行检测。18F-脱氧葡萄糖(18F-fluorodeoxyglucose,18F-FDG) 正电子发射型计算机断层显像/计算机体层成像(positron emission computed tomography,PET/CT)则可以在患者没有条件行有创性基因检测时对EGFR突变状态进行预测评估。本文就18F-FDG PET/CT显像对肺腺癌的EGFR基因突变状态预测的研究进展进行综述。
The research on targeted drugs for primary lung cancer has developed rapidly in recent years. Among them, Epidermal Growth Factor Receptor-tyrosine kinase inhibitors (EGFR-TKIs), which aim on the EGFR gene target, can affect the vast majority of EGFR mutations. Type patients have good effect. However, EGFR-TKIs have little effect on wild-type patients or patients with drug-resistant mutations. Therefore, EGFR mutation status must be detected before targeted therapy. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) can predict EGFR mutation status in patients who are not eligible for invasive genetic testing. This article reviews the research progress of 18F-FDG PET/CT imaging in the prediction of EGFR gene mutation status in lung adenocarcinoma.